Filing Analysis
MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1 and glucagon receptor analog. This stage of the study will utilize 16-week titration cohorts to evaluate dose-escalation strategies and optimize patient tolerability.
Key Facts
- First patient dosed in Part 3 of Phase 1 clinical trial for DA-1726 on April 10, 2026.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors.
- Part 3 consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies.
- The primary goal of this phase is to safely achieve higher target doses and optimize tolerability.
MetaVia Inc. filed a Form 8-K to furnish an updated corporate presentation for March 2026. The presentation is intended for use in upcoming investor communications and conferences.
Key Facts
- The filing was made on March 26, 2026, under Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was posted to the company's investor relations website.
- The presentation is included as Exhibit 99.1 to the filing.
- The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MetaVia Inc. reported its financial results for the fiscal year ended December 31, 2025, and provided a corporate update. The announcement was made via a press release on March 26, 2026, and furnished under Item 2.02.
Key Facts
- Announced financial results for the year ended December 31, 2025
- Provided a corporate update alongside financial results
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- CEO Hyung Heon Kim signed the filing
MetaVia Inc. announced that it has received Institutional Review Board (IRB) approval to commence Phase 1 Part 3 of its clinical trial for DA-1726, a dual GLP-1 and glucagon receptor agonist. The trial will evaluate safety and efficacy in 40 obese subjects, with initial dosing expected in April 2026 and data results anticipated in Q4 2026.
Key Facts
- IRB approval obtained from Clinical Pharmacology of Miami for Phase 1 Part 3 of DA-1726.
- DA-1726 is a novel, dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors.
- The trial will enroll 40 obese, otherwise healthy adult subjects randomized 4:1 (active vs. placebo).
- Part 3A evaluates a one-step titration to 48 mg; Part 3B evaluates a two-step titration to 64 mg.
- Initial dosing is scheduled for April 2026.
- Top-line data readout is expected in the fourth quarter of 2026.